Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

Video content above is prompted by the following:

• What clinical factors do you consider for patients with R/R DLBCL who are primary refractory or experience early relapse in determining transplant eligibility?
  • When CAR T-cell therapy is the best option for your patient, how does the manufacturing process time line affect your decisions?
    • Are most community oncologists referring to CAR T-cell centers or keeping their patients?
    • How early are patients being referred to your center (eg, second-line, third-line)?
    • When do you initiate the collection/production process?
    • What is the primary impetus for early referral?